# NCT03114319 (NCT03114319)

> Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

No report yet. It can be ordered.

- Drugs tested: TNO155; TNO155 plus nazartinib
- Indication: advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03114319
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC); KRAS G12-mutant NSCLC; Esophageal Squamous Cell Cancer (SCC); Head/Neck SCC; Melanoma; Advanced Gastrointestinal Stromal Tumors (GIST); Advanced NRAS/BRAFT wt Cutaneous Melanoma
- Interventions: TNO155; TNO155 in combination with EGF816 (nazartinib)
- Enrollment: 227
- Primary outcome: Number of participants with adverse events and serious adverse events
- Primary outcome: Number of participants with dose limiting toxicities
- Primary outcome: Number of participants with dose interruptions and reductions
- Primary outcome: Dose intensity of study drugs

## Indexed commentary on NCT03114319 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03114319